Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 7, 2025
ADMA Biologics Statement on Tariffs
GlobeNewswire
·
April 7, 2025
RAMSEY, N.J. and BOCA RATON, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics …
iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
GlobeNewswire
·
April 7, 2025
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a first-in-class Activin E antibody shows …
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
GlobeNewswire
·
April 7, 2025
-- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p<0.0001) -- -- -19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years …
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
April 7, 2025
Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelines Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for …
Telix Appoints Paul Schaffer as Chief Technology Officer
GlobeNewswire
·
April 7, 2025
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology …
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 7, 2025
HUNTSVILLE, AL, April 07, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief …
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
GlobeNewswire
·
April 7, 2025
Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants across cardiac biomarkers and functional measures All …
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer
GlobeNewswire
·
April 7, 2025
Mark brings 30 years of experience in R…
Angelini Ventures Appoints Seasoned Life Sciences Investor, Dr. Regina Hodits, as Managing Director
GlobeNewswire
·
April 7, 2025
Accomplished biotech investor with a track record of successful company-building and exits to lead Angelini Ventures’ international BioTech investment strategy Rome, Italy, 7 April 2025 – Angelini Ventures, the corporate venture firm of Angelini …